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Introduction
Osteoporosis, a condition that is usually associated 
with ageing and which is found in postmenopausal 
women, can present during pregnancy and lactation. 
A syndrome of spontaneous fractures that occurred 
in late pregnancy or lactation was first reported by 
Albright and Reifenstein in 1948. In 1955, Nordin and 
Roper published four cases.1 By 2006, there were 
100 cases in the literature.2 We discuss two patients 
who developed multiple vertebral fractures during 
pregnancy and lactation. This paper encompasses 
a review of the current knowledge on calcium and 
vitamin D metabolism in pregnancy, as well as the 
aetiology, clinical features and treatment of this 
condition. Focus is given to the clinical syndrome of 
pregnancy- and lactation-associated osteoporosis. 
A summary is provided of other causes that could be 
responsible for bone loss in pregnancy. 
Case 1
A 30-year-old woman presented 11 weeks after 
delivering her first child with a history of acute onset of 
back pain which had started seven days postpartum. 
She felt the pain while lifting her baby. There was a  loud 
“crack”, accompanied by excruciating back pain. The 
patient was breastfeeding.
Her 58-year-old mother had suffered vertebral fractures. 
There were no other clinical risk factors for osteoporosis.
Magnetic resonance imaging (MRI) (Figure 1) showed 
acute vertebral compression fractures at T11, T12, L1, 
L2, L3 and L4. The dual-energy x-ray absorptiometry 
(DXA) findings are shown in Table I.
Investigations
The patient’s serum calcium and phosphate, 24-hour 
urine calcium, parathyroid hormone (PTH), 25-hy-
droxyvitamin D (25-OH D), liver function and urea and 
electrolytes were all normal.
Treatment
Breastfeeding was discontinued. Calcium (500 mg 
daily) and vitamin D (800 IU) daily were given, as well as 
alendronate 70 mg weekly for six months, followed by 
risedronate 35 mg weekly for 28 months. The decision 
to change to risedronate was made because it has less 
potent binding to hydroxyapatite and octacalcium 
phosphate, and therefore shorter retention in bone 
than alendronate. This profile was thought to be 
preferable for a younger patient. At follow-up DXA 
after 12 and 24 months of risedronate, the BMD in the 
hips remained stable. There was a significant increase 
in lumbar spine density. No further fractures occurred 
and the pain settled over four months.
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Abstract
Pregnancy-and lactation-associated osteoporosis is a rare syndrome of spontaneous fractures occurring in late 
pregnancy or lactation. Early diagnosis and management is essential, because of the severity of the morbidity 
associated with these fractures. Prior to therapy, other reversible causes of osteoporosis should be excluded through 
adequate investigation. Treatment includes cessation of breastfeeding, the provision of adequate pain relief, 
and the use of specific osteoporosis drugs, preferably those with short-term bone retention. Although there is no 
persuasive evidence that calcium and vitamin D requirements increase during pregnancy or lactation compared 
to the non-pregnant woman of childbearing age, it is advisable to ensure that women are vitamin D replete during 
pregnancy and lactation.
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Case 2
A 23-year-old breastfeeding woman presented four 
weeks after the delivery of her first child with a history of 
spontaneous onset of severe back pain.
There was no history of any risk factors for osteoporosis, 
other than that her paternal grandmother had 
osteoporosis. 
MRI  (Figure 2) showed acute vertebral fractures at 
T6, T7, T8, T9, T10, T11 T12 and L1. The DXA findings are 
shown in Table II.
Investigations
The patient’s serum calcium and phosphate, 24-hour 
urine calcium, PTH, 25-OH D, liver function and urea 
and electrolytes were all normal.
Treatment
Breastfeeding was stopped. Calcium (500 mg daily) 
and Vitamin D (800 IU daily) were given, as well as rise-
dronate 35 mg weekly for  12 months. After 12 months 
of risedronate, the bone density increased 13.4% in the 
spine and 3.4% in the total femur. The back pain pro-
gressively improved over the next three months. A fur-
ther pregnancy is being planned.
Discussion
Calcium homeostasis during pregnancy and lactation
Pregnancy and lactation is a special period in a 
woman’s life, when calcium demands are increased to 
accommodate the requirements of the growing foetus 
and the losses that occur in breastmilk during lactation. 
Several excellent reviews on calcium and vitamin D 
requirements during pregnancy and lactation have 
been published recently,3-6 and the reader is referred 
to these for more details.
During pregnancy, the mother must increase her 
calcium retention to allow for the calcium needs of 
the growing foetal skeleton, which at birth contains 
approximately 30 g of calcium. Most of the skeletal 
growth occurs during the third trimester, during which 
roughly 200-250 mg calcium per day is required. It 
Figure 1: Spinal fractures (Case 1) Figure 2: Spinal fracture (Case 2)
Table II: DXA findings (Case 2)
DXA scans                         Z-scores
L1-L4                         -2.9
Femoral neck              -1.7
Total femur                 -2.1
Table I: DXA findings (Case I)
DXA scans                         Z-scores
L1-L4                         -2.7
Femoral neck              -2.4
Total femur                 -2.3
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appears that these increased demands are met mainly 
through increased intestinal calcium absorption, which 
doubles during pregnancy. At present, the mechanisms 
through which this is achieved are unclear, although 
increased 1.25-dihydroxyvitamin D concentrations, 
together with placental lactogen, may play a role. 
During lactation, the increased demand for calcium 
is even higher than during pregnancy. Approximately 
300 mg/day is required to replace the calcium 
that is secreted in the breastmilk. The mechanisms 
through which this demand is met are different to 
those which take place during pregnancy. During 
lactation, intestinal calcium absorption returns to 
pre-pregnancy levels and urinary calcium excretion 
decreases. However, because of low oestrogen and 
high parathyroid hormone-related protein (PTHrP) 
concentrations that are secreted by the breast tissue, 
bone resorption is markedly increased. This results in a 
large calcium efflux from bone, which is then available 
for secretion in the breastmilk. 
The consequence of the mobilisation of calcium from 
bone during lactation is a rapid and consistent fall in 
bone mass, particularly at those sites that are high in 
trabecular bone, such as the vertebral bodies. It has 
been estimated that losses are between 5% and 14% 
of bone mineral content (BMC) or BMD.7,8 These losses 
begin rapidly as soon as lactation commences and 
persist for the duration of lactation. During weaning, 
bone mass rapidly returns to normal, recovering at 
0.5-2% a month. Some researchers have suggested 
that pregnancy and lactation may be associated with 
a higher prevalence of osteoporosis in later life, but this 
has not been substantiated in other studies. 
The effect of calcium supplementation
As far as bone health is concerned, there is little 
evidence to support the contention that calcium 
supplementation influences the rate or extent of bone 
loss that occurs during pregnancy and lactation,5,9 
or the recovery that takes place during weaning.10 
Furthermore, calcium supplements do not appear 
to alter breastmilk calcium concentrations.11 Even in 
populations that consume very low calcium intakes 
(a mean of 280 mg/day), there is no evidence that 
calcium supplementation reduces bone loss during 
lactation or the rate of bone gain in response to 
weaning.9 Although calcium intakes appear to play little 
role in bone health during pregnancy and lactation, 
there is accumulating evidence that in developing 
communities with habitually low calcium intakes, 
calcium supplementation reduces the prevalence of 
gestational hypertension and pre-eclampsia, the risk of 
preterm deliveries and neonatal mortality.4,12
Vitamin D requirements during pregnancy and 
lactation
Recently, there has been considerable discussion 
about the definition of vitamin D deficiency and the 
measurement of vitamin D sufficiency. In response to 
the uncertainties within the literature and the wide 
range of claims that have been made by health 
professionals about the importance of vitamin D in 
preventing cancer, immunological and autoimmune 
disorders and hypertension and diabetes, the Institute 
of Medicine (IOM) in the USA set up a task team to 
review the literature and to make recommendations 
on the dietary requirements for calcium and vitamin D 
throughout the life cycle. The report was released as a 
draft towards the end of 2010 and the final report was 
published in 2011.13 
The report confirms the value of determining serum 
25-OH D as an indicator of vitamin D status, because 
it reflects both dietary intake and the endogenous 
cutaneous production of vitamin D. The panel 
concluded that a serum 25-OH D concentration of 
20 ng/ml (50 nmol/L) is indicative of vitamin D 
sufficiency, while a value < 12 ng/ml (30 nmol/L) is 
indicative of vitamin D deficiency. Further, the panel 
concluded that there is no evidence to suggest that 
pregnant and lactating women have greater vitamin 
D requirements than other women. 
Both animal and human studies suggest that the foetus 
does not require vitamin D for its intrauterine growth or 
calcium homeostasis.14 However, postnatally, the infant 
is very dependent on its vitamin D metabolite store at 
the time of delivery and on acquiring vitamin D through 
cutaneous synthesis, fortified milk formula, breastmilk 
or supplements to maintain its vitamin D status during 
infancy. At birth, neonatal 25-OH D concentrations 
correlate with those of the mother, thus vitamin D 
sufficiency in the mother during pregnancy results in 
a neonate being protected from vitamin D deficiency 
for the first weeks of postnatal life. On the other hand, 
Vitamin D deficiency in the mother predisposes the 
neonate to neonatal hypocalcaemia and to rickets 
during infancy.  
In many countries, numerous articles have highlighted 
the high prevalence of vitamin D deficiency in women 
of childbearing age and during pregnancy, especially 
in Europe in dark-skinned immigrants and in the 
Middle East.15,16 Data for South African women are not 
available. However, information on adolescent black 
and white children in Johannesburg suggests that 
vitamin D deficiency is uncommon in that age group, 
and thus by extrapolation, is probably uncommon in 
healthy adult women.17
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The IOM recommends a dietary vitamin D intake of 
600 IU/day for all women of childbearing age, 
irrespective of whether or not they are pregnant or 
lactating. This recommendation assumes that limited or 
no skin synthesis of vitamin D occurs, which is unlikely to 
be the situation in South Africa. However, in the South 
African situation, few foods are vitamin D fortified, 
thus vitamin D sufficiency can only be achieved 
through cutaneous vitamin D synthesis or vitamin D 
supplements. Therefore, the National Osteopororis 
Foundation of South Africa recommends a vitamin D 
supplement of 800-1000 IU/day, which is very similar 
to the more recently released IOM recommendations 
for pregnant and lactating women in South Africa. 
This is probably appropriate as it will ensure vitamin D 
sufficiency in pregnant and lactating women without 
the need for an individual assessment of vitamin D 
status, which is expensive at present, and without insight 
into the vitamin D status of women of childbearing age 
in relation to geographical region, body composition, 
season or ethnicity.
In summary, currently, there is no persuasive evidence 
to suggest that calcium or vitamin D requirements 
increase during pregnancy or lactation, compared 
to the requirements of non-pregnant women of 
childbearing age. However, it would be prudent 
to ensure that women are vitamin D replete during 
pregnancy and lactation, so as to reduce the risk 
of vitamin D deficiency in the young infant. There is 
also no evidence to suggest that calcium or vitamin 
D supplements above the normal requirements 
reduce the risk of fractures and low bone mass during 
pregnancy and lactation, or speed the recovery of 
bone mass during weaning. 
Clinical presentation
As in the two cases described here, the most common 
presentation is that of a painful vertebral fracture or 
fractures that occur suddenly in late pregnancy or 
during lactation. Usually, they occur in a first pregnancy, 
and although it has been described,1 do not generally 
recur in subsequent pregnancies.1,18 
Aetiology 
The aetiology of this condition still remains unclear. In 
most instances, as these fractures occur in women who 
have no history of having had bone density assessments, 
or having been suspected of having compromised 
bone strength,1,18 it is not certain whether the fractures 
occur because of increased bone resorption occurring 
during pregnancy and lactation, or whether the bone 
quality was compromised prior to the pregnancy. A 
mother had vertebral fractures in one of the two cases 
presented in this report. Dunne et al19 report on there 
being a greater incidence of fractures that occur  in 
the mothers of 35 patients with pregnancy-associated 
osteoporosis than in the mothers of controls. Genetic 
factors could therefore be implicated. 
It has been suggested that raised PTHrP may play a role 
in increasing bone resorption.1,18 As described above, 
PTHrP is raised during late pregnancy and lactation. 
This, together with low estradiol levels during lactation, 
could significantly increase bone loss. The fact that in 
most instances the bone loss reverses after pregnancy 
supports the postulate that bone loss is a consequence 
of changes in pregnancy which increase bone 
resorption.3,20
Another aetiology that has been postulated is a 
genetic deficiency of calcitonin or its receptor.18
It is also possible that in a patient with an already 
compromised bone density, the mechanical stresses of 
late pregnancy may contribute to fractures occurring 
at that time. 
Investigation 
The diagnosis of pregnancy- and lactation-associated 
osteoporosis should be entertained in any patient who 
presents with severe backache during late pregnancy 
or lactation. Typically, X-ray imaging of the thoracic 
and lumbar spine demonstrates multiple biconcave 
fragility fractures, but fractures may also be present in 
the ribs, pelvis or hips. The diagnosis can be confirmed 
by central DXA, which usually demonstrates very low 
spinal bone density and low bone density at the hip. The 
use of MRI to diagnose fractures is preferable as in the 
majority of these cases, previous X-rays are not likely to 
be available to exclude prior fractures.  MRI, with the use 
of short TI inversion recovery sequence and the ability 
to show oedema, allows the recency of the fractures to 
be determined. There are no other diagnostic criteria, 
but it is essential to eliminate other secondary causes 
of bone loss. Calcium homeostasis should be fully 
investigated, including assessment of dietary calcium 
intake and the serum 25-OH D level. Euthyroidism 
should be confirmed and primary hyperparathyroidism 
excluded. Bone loss that is secondary to malignancy is 
uncommon in pregnancy, but should be considered. 
It is advisable to carry out protein electrophoreses 
to exclude myeloma. Biochemical markers of bone 
turnover may be increased at the time of diagnosis 
and can be used to monitor the course of the disease 
potentially.
Management
If secondary causes of osteoporosis have been found, 
they should be treated. Numerous drugs have been 
Case Study: Pregnancy- and lactation-associated osteoporosis
153 2012 Volume 17 No 3JEMDSA
used to manage patients with pregnancy- and lacta-
tion-associated osteoporosis. These include bisphos-
phonates,1,2,21 teriparatide,22 strontium ranelate,23 cal-
citonin18 and calcium and vitamin D.18 O’Sullivan et 
al,2 in their review of patients who were treated with 
bisphosphonates, advocated treatment with bisphos-
phonates as it led to a greater increase in bone density 
than would be expected with conservative manage-
ment. However, Kovacs18 highlighted that given the 
low numbers of reported cases and the lack of control 
data, the efficacy of any specific treatment could not 
be assessed. As the majority of patients resolve spon-
taneously with conservative management, he sug-
gested that intervention was not warranted, other than 
in desperate situations. Conservative measures include 
the cessation of breastfeeding and providing relief for 
the severe pain that is associated with fractures. As no 
comparative data are available, no firm conclusion 
can be reached as to whether or not active or con-
servative measures represent the treatment of choice. 
However, based on the limited available case reports, 
in the case of the patient who has developed verte-
bral fractures and who is of a young age, best clinical 
practice would be to treat her for one to two years with 
agents that are known to have short-term bone reten-
tion, such as risedronate, strontium ranelate or deno-
sumab, rather than agents with long-term bone reten-
tion, such as alendronate or zoledronic acid.  
Other conditions associated with bone loss in 
pregnancy
During pregnancy and the puerperium, heparin is 
commonly used as prophylaxis in patients who are 
at risk of venous thrombosis and in women with a 
history of poor obstetric outcome and recurrent 
foetal loss because of thrombophilia. The long-term 
use of unfractioned heparin in pregnancy has been 
associated with a 2.2-5% incidence of heparin-induced 
osteoporotic fracture, but data are scarce for low-
molecular-weight heparin. Also, there is lack of clarity 
on the risk of osteoporosis and osteoporotic fractures.24 
Transient osteoporosis of the hip is a distinct entity. It is 
a rare condition. Only 200 cases have been reported 
in men and women. It can occur in pregnancy or early 
postpartum and presents as pain in the hip or a limp. 
Usually, it is self-limiting and responds to conservative 
measures and bed rest. Resolution of symptoms and 
radiological changes occurs within a few months.18 
Conclusion
Pregnancy- and lactation-associated osteoporosis is a 
rare cause of spontaneous vertebral fragility fractures. 
The presented cases support the body of evidence 
that confirms the severity of this condition and the 
importance of having a high index of suspicion in 
patients who present with back pain in pregnancy and 
during lactation. 
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